blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2443255

EP2443255 - CSF1R-DERIVED POLYNUCLEOTIDES FOR MEDICAL USE [Right-click to bookmark this link]
Former [2012/17]POLYNUCLEOTIDES CHARACTERISED BY THE SEQUENCE OF CSFLR GENE AND LTR DERIVED SEQUENCE FOR MEDICAL USE
[2016/15]
StatusNo opposition filed within time limit
Status updated on  02.02.2018
Database last updated on 26.06.2024
FormerThe patent has been granted
Status updated on  24.02.2017
FormerGrant of patent is intended
Status updated on  17.02.2017
Most recent event   Tooltip10.07.2020Lapse of the patent in a contracting state
New state(s): AL		published on 12.08.2020  [2020/33]
Applicant(s)For all designated states
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Robert-Rössle-Straße 10
13125 Berlin / DE
[N/P]
Former [2016/43]For all designated states
Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft
Robert-Rössle-Strasse 10
13125 Berlin / DE
Former [2012/17]For all designated states
Max-Delbrück-Centrum für Molekulare Medizin Berlin-Buch
Robert-Rössle-Str. 10
13092 Berlin / DE
Inventor(s)01 / MATHAS, Stephan
c/o Max-Delbrück-Centrum fü Molekulare
Medizin in der Helmholtz-Gemeinschaft
Robert -Rössle- Strasse 10
13125 Berlin / DE
02 / LAMPRECHT, Björn
c/o Max-Delbrück-Centrum für Molekulare
Medizin in der Helmholtz-Gemeinschaft
Robert- Rössle -Strasse 10
13125 Berlin / DE
03 / DÖRKEN, Bernd
c/o Max-Delbrück-Centrum für Molekulare
Medizin in der Helmholtz-Gemeinschaft
Robert- Rössle -Strasse 10
13125 Berlin / DE
04 / BONIFER, Constanze
School of Cancer Sciences
Institute of Biomedical Research
College of Medical and Dental Sciences
University of Birmingham
Birmingham, B15 2TT / GB
 [2016/44]
Former [2012/17]01 / MATHAS, Stephan
c/o Max-delbrück-centrum Für Molekulare Medizin
Berlin-buch
Robert Rössle Strasse 10
13092 Berlin / DE
02 / LAMPRECHT, Björn
c/o Max-delbrück-centrum Für Molekulare Medizin
Berlin-buch
Robert Rössle Strasse 10
13092 Berlin / DE
03 / DÖRKEN, Bernd
c/o Max-delbrück-centrum Für Molekulare Medizin
Berlin-buch
Robert Rössle Strasse 10
13092 Berlin / DE
04 / BONIFER, Constanze
School of Cancer Sciences
Institute of Biomedical Research
College of Medical and Dental Sciences
University of Birmingham
Birmingham, B15 2TT / GB
Representative(s)Hoppe, Georg Johannes
Darani Anwaltskanzlei
Hohenzollerndamm 117
14199 Berlin / DE
[N/P]
Former [2017/13]Hoppe, Georg Johannes
Darani Anwaltskanzlei
Beuckestrasse 20
14163 Berlin / DE
Former [2012/17]Hoppe, Georg Johannes
darani Anwaltskanzlei Beuckestrasse 20
14163 Berlin / DE
Application number, filing date10735185.021.06.2010
[2017/13]
WO2010EP03714
Priority number, dateEP2009000808219.06.2009         Original published format: EP 09008082
EP2010000458730.04.2010         Original published format: EP 10004587
[2012/17]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2010145839
Date:23.12.2010
Language:EN
[2010/51]
Type: A2 Application without search report 
No.:EP2443255
Date:25.04.2012
Language:EN
The application published by WIPO in one of the EPO official languages on 23.12.2010 takes the place of the publication of the European patent application.
[2012/17]
Type: B1 Patent specification 
No.:EP2443255
Date:29.03.2017
Language:EN
[2017/13]
Search report(s)International search report - published on:EP17.02.2011
ClassificationIPC:C12Q1/68
[2012/17]
CPC:
A61P35/00 (EP); C12Q1/6886 (EP,US); C12Q2600/154 (EP,US);
C12Q2600/156 (EP,US)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   SM,   TR [2012/17]
Extension statesBANot yet paid
MENot yet paid
RSNot yet paid
TitleGerman:CSF1R-BASIERTE POLYNUKLEOTIDE FÜR MEDIZINISCHE ZWECKE[2016/36]
English:CSF1R-DERIVED POLYNUCLEOTIDES FOR MEDICAL USE[2016/41]
French:POLYNUCLÉOTIDES DERIVES DE CSF1R POUR UN USAGE MÉDICAL[2016/36]
Former [2012/17]MITTELS CSFLR-GENSEQUENZ UND LTR-DERIVIERTER SEQUENZ CHARAKTERISIERTE POLYNUKLEOTIDE FÜR MEDIZINSICHE ZWECKE
Former [2012/17]POLYNUCLEOTIDES CHARACTERISED BY THE SEQUENCE OF CSFLR GENE AND LTR DERIVED SEQUENCE FOR MEDICAL USE
Former [2012/17]POLYNUCLÉOTIDES POUR UN USAGE MÉDICAL
Entry into regional phase12.01.2012National basic fee paid 
12.01.2012Designation fee(s) paid 
12.01.2012Examination fee paid 
Examination procedure12.01.2012Examination requested  [2012/17]
20.07.2012Amendment by applicant (claims and/or description)
08.10.2012Despatch of a communication from the examining division (Time limit: M02)
06.12.2012Reply to a communication from the examining division
10.09.2013Despatch of a communication from the examining division (Time limit: M06)
18.03.2014Reply to a communication from the examining division
14.04.2014Despatch of a communication from the examining division (Time limit: M06)
24.10.2014Reply to a communication from the examining division
24.11.2014Despatch of a communication from the examining division (Time limit: M04)
02.03.2015Reply to a communication from the examining division
19.08.2015Despatch of a communication from the examining division (Time limit: M06)
26.02.2016Reply to a communication from the examining division
24.05.2016Communication of intention to grant the patent
29.07.2016Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
05.10.2016Communication of intention to grant the patent
13.02.2017Fee for grant paid
13.02.2017Fee for publishing/printing paid
13.02.2017Receipt of the translation of the claim(s)
Divisional application(s)The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  08.10.2012
Opposition(s)03.01.2018No opposition filed within time limit [2018/10]
Fees paidRenewal fee
27.06.2012Renewal fee patent year 03
17.06.2013Renewal fee patent year 04
16.05.2014Renewal fee patent year 05
25.06.2015Renewal fee patent year 06
31.03.2016Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU21.06.2010
AL29.03.2017
AT29.03.2017
CY29.03.2017
CZ29.03.2017
DK29.03.2017
EE29.03.2017
ES29.03.2017
FI29.03.2017
HR29.03.2017
IT29.03.2017
LT29.03.2017
LV29.03.2017
MC29.03.2017
MK29.03.2017
NL29.03.2017
PL29.03.2017
RO29.03.2017
SE29.03.2017
SI29.03.2017
SK29.03.2017
SM29.03.2017
TR29.03.2017
IE21.06.2017
LU21.06.2017
MT21.06.2017
BG29.06.2017
NO29.06.2017
BE30.06.2017
GR30.06.2017
IS29.07.2017
PT31.07.2017
[2020/33]
Former [2020/15]HU21.06.2010
AT29.03.2017
CY29.03.2017
CZ29.03.2017
DK29.03.2017
EE29.03.2017
ES29.03.2017
FI29.03.2017
HR29.03.2017
IT29.03.2017
LT29.03.2017
LV29.03.2017
MC29.03.2017
MK29.03.2017
NL29.03.2017
PL29.03.2017
RO29.03.2017
SE29.03.2017
SI29.03.2017
SK29.03.2017
SM29.03.2017
TR29.03.2017
IE21.06.2017
LU21.06.2017
MT21.06.2017
BG29.06.2017
NO29.06.2017
BE30.06.2017
GR30.06.2017
IS29.07.2017
PT31.07.2017
Former [2019/51]HU21.06.2010
AT29.03.2017
CY29.03.2017
CZ29.03.2017
DK29.03.2017
EE29.03.2017
ES29.03.2017
FI29.03.2017
HR29.03.2017
IT29.03.2017
LT29.03.2017
LV29.03.2017
MC29.03.2017
MK29.03.2017
NL29.03.2017
PL29.03.2017
RO29.03.2017
SE29.03.2017
SI29.03.2017
SK29.03.2017
SM29.03.2017
IE21.06.2017
LU21.06.2017
MT21.06.2017
BG29.06.2017
NO29.06.2017
BE30.06.2017
GR30.06.2017
IS29.07.2017
PT31.07.2017
Former [2019/46]HU21.06.2010
AT29.03.2017
CY29.03.2017
CZ29.03.2017
DK29.03.2017
EE29.03.2017
ES29.03.2017
FI29.03.2017
HR29.03.2017
IT29.03.2017
LT29.03.2017
LV29.03.2017
MC29.03.2017
NL29.03.2017
PL29.03.2017
RO29.03.2017
SE29.03.2017
SI29.03.2017
SK29.03.2017
SM29.03.2017
IE21.06.2017
LU21.06.2017
MT21.06.2017
BG29.06.2017
NO29.06.2017
BE30.06.2017
GR30.06.2017
IS29.07.2017
PT31.07.2017
Former [2019/31]HU21.06.2010
AT29.03.2017
CZ29.03.2017
DK29.03.2017
EE29.03.2017
ES29.03.2017
FI29.03.2017
HR29.03.2017
IT29.03.2017
LT29.03.2017
LV29.03.2017
MC29.03.2017
NL29.03.2017
PL29.03.2017
RO29.03.2017
SE29.03.2017
SI29.03.2017
SK29.03.2017
SM29.03.2017
IE21.06.2017
LU21.06.2017
MT21.06.2017
BG29.06.2017
NO29.06.2017
BE30.06.2017
GR30.06.2017
IS29.07.2017
PT31.07.2017
Former [2018/43]AT29.03.2017
CZ29.03.2017
DK29.03.2017
EE29.03.2017
ES29.03.2017
FI29.03.2017
HR29.03.2017
IT29.03.2017
LT29.03.2017
LV29.03.2017
MC29.03.2017
NL29.03.2017
PL29.03.2017
RO29.03.2017
SE29.03.2017
SI29.03.2017
SK29.03.2017
SM29.03.2017
IE21.06.2017
LU21.06.2017
MT21.06.2017
BG29.06.2017
NO29.06.2017
BE30.06.2017
GR30.06.2017
IS29.07.2017
PT31.07.2017
Former [2018/39]AT29.03.2017
CZ29.03.2017
DK29.03.2017
EE29.03.2017
ES29.03.2017
FI29.03.2017
HR29.03.2017
IT29.03.2017
LT29.03.2017
LV29.03.2017
MC29.03.2017
NL29.03.2017
PL29.03.2017
RO29.03.2017
SE29.03.2017
SI29.03.2017
SK29.03.2017
SM29.03.2017
IE21.06.2017
LU21.06.2017
BG29.06.2017
NO29.06.2017
BE30.06.2017
GR30.06.2017
IS29.07.2017
PT31.07.2017
Former [2018/23]AT29.03.2017
CZ29.03.2017
DK29.03.2017
EE29.03.2017
ES29.03.2017
FI29.03.2017
HR29.03.2017
IT29.03.2017
LT29.03.2017
LV29.03.2017
MC29.03.2017
NL29.03.2017
PL29.03.2017
RO29.03.2017
SE29.03.2017
SI29.03.2017
SK29.03.2017
SM29.03.2017
IE21.06.2017
LU21.06.2017
BG29.06.2017
NO29.06.2017
GR30.06.2017
IS29.07.2017
PT31.07.2017
Former [2018/21]AT29.03.2017
CZ29.03.2017
DK29.03.2017
EE29.03.2017
ES29.03.2017
FI29.03.2017
HR29.03.2017
IT29.03.2017
LT29.03.2017
LV29.03.2017
MC29.03.2017
NL29.03.2017
PL29.03.2017
RO29.03.2017
SE29.03.2017
SK29.03.2017
SM29.03.2017
LU21.06.2017
BG29.06.2017
NO29.06.2017
GR30.06.2017
IS29.07.2017
PT31.07.2017
Former [2018/11]AT29.03.2017
CZ29.03.2017
DK29.03.2017
EE29.03.2017
ES29.03.2017
FI29.03.2017
HR29.03.2017
IT29.03.2017
LT29.03.2017
LV29.03.2017
MC29.03.2017
NL29.03.2017
PL29.03.2017
RO29.03.2017
SE29.03.2017
SK29.03.2017
SM29.03.2017
BG29.06.2017
NO29.06.2017
GR30.06.2017
IS29.07.2017
PT31.07.2017
Former [2018/09]AT29.03.2017
CZ29.03.2017
DK29.03.2017
EE29.03.2017
ES29.03.2017
FI29.03.2017
HR29.03.2017
IT29.03.2017
LT29.03.2017
LV29.03.2017
NL29.03.2017
PL29.03.2017
RO29.03.2017
SE29.03.2017
SK29.03.2017
SM29.03.2017
BG29.06.2017
NO29.06.2017
GR30.06.2017
IS29.07.2017
PT31.07.2017
Former [2017/51]AT29.03.2017
CZ29.03.2017
EE29.03.2017
ES29.03.2017
FI29.03.2017
HR29.03.2017
IT29.03.2017
LT29.03.2017
LV29.03.2017
NL29.03.2017
PL29.03.2017
RO29.03.2017
SE29.03.2017
SK29.03.2017
SM29.03.2017
BG29.06.2017
NO29.06.2017
GR30.06.2017
IS29.07.2017
PT31.07.2017
Former [2017/50]AT29.03.2017
CZ29.03.2017
EE29.03.2017
ES29.03.2017
FI29.03.2017
HR29.03.2017
IT29.03.2017
LT29.03.2017
LV29.03.2017
NL29.03.2017
PL29.03.2017
RO29.03.2017
SE29.03.2017
SK29.03.2017
BG29.06.2017
NO29.06.2017
GR30.06.2017
IS29.07.2017
Former [2017/49]AT29.03.2017
CZ29.03.2017
EE29.03.2017
ES29.03.2017
FI29.03.2017
HR29.03.2017
IT29.03.2017
LT29.03.2017
LV29.03.2017
NL29.03.2017
RO29.03.2017
SE29.03.2017
SK29.03.2017
BG29.06.2017
NO29.06.2017
GR30.06.2017
IS29.07.2017
Former [2017/48]CZ29.03.2017
FI29.03.2017
HR29.03.2017
LT29.03.2017
LV29.03.2017
NL29.03.2017
SE29.03.2017
BG29.06.2017
NO29.06.2017
GR30.06.2017
Former [2017/41]FI29.03.2017
HR29.03.2017
LT29.03.2017
LV29.03.2017
NL29.03.2017
SE29.03.2017
BG29.06.2017
NO29.06.2017
GR30.06.2017
Cited inInternational search[XA]US7429451  (NAKAGAWARA AKIRA [JP], et al) [X] 1,2 * sequence 23 * [A] 3-19
 [XAI]  - AHARINEJAD SEYEDHOSSEIN ET AL, "Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice.", CANCER RESEARCH 1 AUG 2004 LNKD- PUBMED:15289345, (20040801), vol. 64, no. 15, ISSN 0008-5472, pages 5378 - 5384, XP002610330 [X] 18 * abstract * [A] 1-15 [I] 16,17,19

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-04-0961
 [XP]  - LAMPRECHT BJÖRN ET AL, "Derepression of an endogenous long terminal repeat activates the CSF1R proto-oncogene in human lymphoma.", NATURE MEDICINE MAY 2010 LNKD- PUBMED:20436485, (201005), vol. 16, no. 5, ISSN 1546-170X, pages 571 - 579 , 1P, XP002610331 [XP] 1-19 * the whole document *

DOI:   http://dx.doi.org/10.1038/NM.2129
 [XA]  - WANG YONGMEI ET AL, "Role of IGF-I signaling in regulating osteoclastogenesis.", JOURNAL OF BONE AND MINERAL RESEARCH : THE OFFICIAL JOURNAL OF THE AMERICAN SOCIETY FOR BONE AND MINERAL RESEARCH SEP 2006 LNKD- PUBMED:16939393, (200609), vol. 21, no. 9, ISSN 0884-0431, pages 1350 - 1358, XP002610332 [X] 15 * abstract * * page 1352, column 2 * [A] 1-14,16-19

DOI:   http://dx.doi.org/10.1359/JBMR.060610
Examination   - HEISTERKAMP N ET AL, "Isolation of v-fms and its human cellular homolog", VIROLOGY, ELSEVIER, AMSTERDAM, NL, vol. 126, no. 1, doi:10.1016/0042-6822(83)90476-2, ISSN 0042-6822, (19830415), pages 248 - 258, (19830415), XP023057735

DOI:   http://dx.doi.org/10.1016/0042-6822(83)90476-2
by applicantWO2008058341
    - MATHAS, S. ET AL., PNAS, (2009), vol. 106, pages 5831 - 5836
    - JURKA, J. ET AL., CYTOGENETIC AND GENOME RESEARCH, (2005), vol. 110, pages 462 - 267
    - MATHAS, S.; KREHER, S.; MEABURN, K.J.; JOHRENS, K.; LAMPRECHT, B.; ASSAF, C.; STERRY, W.; KADIN, M.E.; DAIBATA, M.; JOOS, S. ET AL, "Gene deregulation and spatial genome reorganization near breakpoints prior to formation of translocations in anaplastic large cell lymphoma", PNAS, (2009), vol. 106, pages 5831 - 58369
    - LIN, E.Y.; NGUYEN, A.; RUSSELL, R.G.; POLLARD, J.W., "Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy", J. EXP. MED., (2001), vol. 193, doi:doi:10.1084/jem.193.6.727, pages 727 - 740, XP055059258

DOI:   http://dx.doi.org/10.1084/jem.193.6.727
    - SMIT, A.F., NUCLEIC ACIDS RES., (1993), vol. 21, pages 1863 - 1872
    - SCHMIDT, W.M. ET AL., NUCLEIC ACIDS RES., (1996), vol. 24, pages 1789 - 1791
    - BAGG, A, "Lineage ambiguity, infidelity, and promiscuity in immunophenotypically complex acute leukemias: genetic and morphologic correlates", AM J CLIN PATHOL, (2007), vol. 128, pages 545 - 548
    - BONIFER, C.; HUME, D. A., "The transcriptional regulation of the Colony-Stimulating Factor 1 Receptor (csflr) gene during hematopoiesis", FRONT BIOSCI, (2008), vol. 13, pages 549 - 560
    - BORZILLO, G. V.; ASHMUN, R. A.; SHERR, C. J., "Macrophage lineage switching of murine early pre-B lymphoid cells expressing transduced fms genes", MOL CELL BIOL, (1990), vol. 10, pages 2703 - 2714
    - BURNS, C. J.; HARTE, M. F.; BU, X.; FANTINO, E.; GIARRUSSO, M.; JOFFE, M.; KUREK, M.; LEGGE, F. S.; RAZZINO, P.; SU, S. ET AL., "Discovery of 2-(alpha-methylbenzylamino) pyrazines as potent Type II inhibitors of FMS", BIOORG MED CHEM LETT, (2009), vol. 19, doi:doi:10.1016/j.bmcl.2008.12.073, pages 1206 - 1209, XP025937247

DOI:   http://dx.doi.org/10.1016/j.bmcl.2008.12.073
    - CHYLA, B. J.; MORENO-MIRALLES, I.; STEAPLETON, M. A.; THOMPSON, IVI. A.; BHASKARA, S.; ENGEL, M.; HIEBERT, S. W., "Deletion of Mtgl6, a target of t(16;21), alters hematopoietic progenitor cell proliferation and lineage allocation", MOL CELL BIOL, (2008), vol. 28, pages 6234 - 6247
    - COBALEDA, C.; JOCHUM, W.; BUSSLINGER, M., "Conversion of mature B cells into T cells by dedifferentiation to uncommitted progenitors", NATURE, (2007), vol. 449, doi:doi:10.1038/nature06159, pages 473 - 477, XP055291303

DOI:   http://dx.doi.org/10.1038/nature06159
    - DAI, X. M.; RYAN, G. R.; HAPEL, A. J.; DOMINGUEZ, M. G.; RUSSELL, R. G.; KAPP, S.; SYLVESTRE, V.; STANLEY, E. R., "Targeted disruption of the mouse colony-stimulating factor 1 receptor gene results in osteopetrosis, mononuclear phagocyte deficiency, increased primitive progenitor cell frequencies, and reproductive defects", BLOOD, (2002), vol. 99, doi:doi:10.1182/blood.V99.1.111, pages 111 - 120, XP002505054

DOI:   http://dx.doi.org/10.1182/blood.V99.1.111
    - DELHASE, M.; HAYAKAWA, M.; CHEN, Y.; KARIN, M., "Positive and negative regulation of IkappaB kinase activity through IKKbeta subunit phosphorylation", SCIENCE, (1999), vol. 284, pages 309 - 313
    - DOWNING, J. R.; SHURTLEFF, S. A.; SHERR, C. J., "Peptide antisera to human colony-stimulating factor 1 receptor detect ligand-induced conformational changes and a binding site for phosphatidylinositol 3-kinase", MOL CELL BIOL, (1991), vol. 11, pages 2489 - 2495
    - DRUKER, R.; WHITELAW, E., "Retrotransposon-derived elements in the mammalian genome: a potential source of disease", J INHERIT METAB DIS, (2004), vol. 27, pages 319 - 330
    - EDEN, A.; GAUDET, F.; WAGHMARE, A.; JAENISCH, R., "Chromosomal instability and tumors promoted by DNA hypomethylation", SCIENCE, (2003), vol. 300, page 455
    - EHLERS, A.; OKER, E.; BENTINK, S.; LENZE, D.; STEIN, H.; HUMMEL, M., "Histone acetylation and DNA demethylation of B cells result in a Hodgkin-like phenotype", LEUKEMIA, (2008), vol. 22, pages 835 - 841
    - EHRLICH, M., "DNA methylation in cancer: too much, but also too little", ONCOGENE, (2002), vol. 21, doi:doi:10.1038/sj.onc.1205651, pages 5400 - 5413, XP001188228

DOI:   http://dx.doi.org/10.1038/sj.onc.1205651
    - ESTELLER, M, "CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future", ONCOGENE, (2002), vol. 21, pages 5427 - 5440
    - FAN, T.; SCHMIDTMANN, A.; XI, S.; BRIONES, V.; ZHU, H.; SUH, H. C.; GOOYA, J.; KELLER, J. R.; XU, H.; ROAYAEI, J. ET AL., "DNA hypomethylation caused by Lsh deletion promotes erythroleukemia development", EPIGENETICS, (2008), vol. 3, pages 134 - 142
    - FAULKNER, G. J.; KIMURA, Y.; DAUB, C. 0.; WANI, S.; PLESSY, C.; IRVINE, K. M.; SCHRODER, K.; CLOONAN, N.; STEPTOE, A. L.; LASSMANN, "The regulated retrotransposon transcriptome of mammalian cells", NAT GENET, (2009), vol. 41, pages 563 - 571
    - FELDMAN, A. L.; ARBER, D. A.; PITTALUGA, S.; MARTINEZ, A.; BURKE, J. S.; RAFFELD, M.; CAMOS, M.; WARNKE, R.; JAFFE, E. S., "Clonally related follicular lymphomas and histiocytic/dendritic cell sarcomas: evidence for transdifferentiation of the follicular lymphoma clone", BLOOD, (2008), vol. 111, pages 5433 - 5439
    - FOLLOWS, G. A.; TAGOH, H.; LEFEVRE, P.; MORGAN, G. J.; BONIFER, C., "Differential transcription factor occupancy but evolutionarily conserved chromatin features at the human and mouse M-CSF (CSF-1) receptor loci", NUCLEIC ACIDS RES, (2003), vol. 31, pages 5805 - 5816
    - GAMOU, T.; KITAMURA, E.; HOSODA, F.; SHIMIZU, K.; SHINOHARA, K.; HAYASHI, Y.; NAGASE, T.; YOKOYAMA, Y.; OHKI, M., "The partner gene of AML1 in t(16;21) myeloid malignancies is a novel member of the MTG8(ETO) family", BLOOD, (1998), vol. 91, pages 4028 - 4037
    - GOARDON, N.; LAMBERT, J. A.; RODRIGUEZ, P.; NISSAIRE, P.; HERBLOT, S.; THIBAULT, P.; DUMENIL, D.; STROUBOULIS, J.; ROMEO, P. H.; H, "ETO2 coordinates cellular proliferation and differentiation during erythropoiesis", EMBO J, (2006), vol. 25, pages 357 - 366
    - HINZ, M.; LEMKE, P.; ANAGNOSTOPOULOS, I.; HACKER, C.; KRAPPMANN, D.; MATHAS, S.; DORKEN, B.; ZENKE, M.; STEIN, H.; SCHEIDEREIT, C., "Nuclear factor kappaB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity", J EXP MED, (2002), vol. 196, doi:doi:10.1084/jem.20020062, pages 605 - 617, XP002286321

DOI:   http://dx.doi.org/10.1084/jem.20020062
    - HOPKEN, U. E.; FOSS, H. D.; MEYER, D.; HINZ, M.; LEDER, K.; STEIN, H.; LIPP, M., "Up-regulation of the chemokine receptor CCR7 in classical but not in lymphocyte-predominant Hodgkin disease correlates with distinct dissemination of neoplastic cells in lymphoid organs", BLOOD, (2002), vol. 99, doi:doi:10.1182/blood.V99.4.1109, pages 1109 - 1116, XP002292389

DOI:   http://dx.doi.org/10.1182/blood.V99.4.1109
    - HOWARD, G.; EIGES, R.; GAUDET, F.; JAENISCH, R.; EDEN, A., "Activation and transposition of endogenous retroviral elements in hypomethylation induced tumors in mice.", ONCOGENE, (2008), vol. 27, pages 404 - 408
    - HUANG, J.; FAN, T.; YAN, Q.; ZHU, H.; FOX, S.; ISSAQ, H. J.; BEST, L.; GANGI, L.; MUNROE, D.; MUEGGE, K., "Lsh, an epigenetic guardian of repetitive elements", NUCLEIC ACIDS RES, (2004), vol. 32, pages 5019 - 5028
    - HUG, B. A.; LAZAR, M. A., "ETO interacting proteins", ONCOGENE, (2004), vol. 23, pages 4270 - 4274
    - IKAWA, T.; KAWAMOTO, H.; WRIGHT, L. Y.; MURRE, C., "Long-term cultured E2A-deficient hematopoietic progenitor cells are pluripotent", IMMUNITY, (2004), vol. 20, doi:doi:10.1016/S1074-7613(04)00049-4, pages 349 - 360, XP009157675

DOI:   http://dx.doi.org/10.1016/S1074-7613(04)00049-4
    - IRVINE, K. M.; BURNS, C. J.; WILKS, A. F.; SU, S.; HUME, D. A.; SWEET, M. J., "A CSF-1 receptor kinase mhibitor targets effector functions and inhibits pro-inflammatory cytokine production from murine macrophage populations", FASEH J, (2006), vol. 20, doi:doi:10.1096/fj.06-5848fje, pages 1921 - 1923, XP055189830

DOI:   http://dx.doi.org/10.1096/fj.06-5848fje
    - JANZ, M.; DöRKEN, B.; MATHAS, S., "Reprogramming of B lymphoid cells in human lymphoma pathogenesis", CELL CYCLE, (2006), vol. 5, doi:doi:10.4161/cc.5.10.2737, pages 1057 - 1061, XP055022538

DOI:   http://dx.doi.org/10.4161/cc.5.10.2737
    - JERN, P.; COFFIN, J. M., "Effects of retroviruses on host genome function", ANNU REV GENET, (2008), vol. 42, pages 709 - 732
    - JONES, P. A.; BAYLIN, S. B., "The fundamental role of epigenetic events in cancer", NAT REV GENET, (2002), vol. 3, pages 415 - 428, XP008042555
    - JOOS, S.; MENZ, C. K.; WROBEL, G.; SIEBERT, R.; GESK, S.; OW, S.; MECHTERSHEIMER, G.; TRUMPER, L.; MOLLER, P.; LICHTER, P., "Classical Hodgkin lymphoma is characterized by recurrent copy number gains of the short ann of chromosome 2", BLOOD, (2002), vol. 99, pages 1381 - 1387
    - JUNDT, F.; KLEY, K.; ANAGNOSTOPOULOS, I.; SCHULZE PROBSTING, K.; GREINER, A.; MATHAS, S.; SCHEIDEREIT, C.; WIRTH, T.; STEIN, H.; D, "Loss of PU.1 expression is associated with defective immunoglobulin transcription in Hodgkin and Reed-Sternberg cells of classical Hodgkin disease", BLOOD, (2002), vol. 99, pages 3060 - 3062
    - KOCHETKOVA, M.; MCKENZIE, O. L.; BAIS, A. J.; MARTIN, J. M.; SECKER, G. A.; SESHADRI, R.; POWELL, J. A.; HINZE, S. J.; GARDNER, A., "CBFA2T3 (MTG16) is a putative breast tumor suppressor gene from the breast cancer loss of heterozygosity region at 16q24.3", CANCER RES, (2002), vol. 62, pages 4599 - 4604
    - KUMAR, R.; CHENEY, K. M.; MCKIRDY, R.; NEILSEN, P. M.; SCHULZ, R. B.; LEE, J.; COHEN, J.; BOOKER, G. W.; CALLEN, D. F., "CBFA2T3-ZNF652 corepressor complex regulates transcription of the E-box gene HEB", J BIOL CHEM, (2008), vol. 283, pages 19026 - 19038
    - KüPPERS, R., "The biology of Hodgkin's lymphoma", NAT REV CANCER, (2009), vol. 9, doi:doi:10.1038/nrc2542, pages 15 - 27, XP055195906

DOI:   http://dx.doi.org/10.1038/nrc2542
    - KUPPERS, R.; KLEIN, U.; SCHWERING, I.; DISTLER, V.; BRAUNINGER, A.; CATTORETTI, G.; TU, Y.; STOLOVITZKY, G. A.; CALIFANO, A.; HANS, "Identification of Hodgkin and Reed-Sternberg cell-specific genes by gene expression profiling", J CLIN INVEST, (2003), vol. 111, pages 529 - 537
    - LEE, S. H.; WANG, X.; DEJONG, J., "Functional interactions between an atypical NF-kappaB site from the rat CYP2B1 promoter and the transcriptional repressor RBP-Jkappa/CBFI", NUCLEIC ACIDS RES, (2000), vol. 28, pages 2091 - 2098
    - LEGRAND, 0.; PERROT, J. Y.; SIMONIN, G.; BAUDARD, M.; CADIOU, M.; BLANC, C.; RAMOND, S.; VIGUIE, F.; MARIE, J. P; ZITTOUN, R., "Adult biphenotypic acute leukaemia: an entity with poor prognosis which is related to unfavourable cytogenetics and P-glycoprotein over-expression", BR J HAEMATOL, (1998), vol. 100, pages 147 - 155
    - LI, X.; MASSA, P. E.; HANIDU, A.; PEET, G. W.; ARO, P.; SAVITT, A.; MISCHE, S.; LI, J.; MARCU, K. B., "IKKalpha, IKKbeta, and NEMO/IKKgamma are each required for the NF-kappa B-mediated inflammatory response program", J BIOL CHEM, (2002), vol. 277, pages 45129 - 45140
    - MACLEOD, R. A.; SPITZER, D.; BAR-AM, I.; SYLVESTER, J. E.; KAUFMANN, M.; WERNICH, A.; DREXLER, H. G., "Karyotypic dissection of Hodgkin's disease cell lines reveals ectopic subtelomeres and ribosomal DNA at sites of multiple jumping translocations and genomic amplification", LEUKEMIA, (2000), vol. 14, pages 1803 - 1814
    - MAKSAKOVA, 1. A.; MAGER, D. L.; REISS, D., "Keeping active endogenous retroviral-like elements in check: the epigenetic perspective", CELL MOL LIFE SCI, (2008), vol. 65, pages 3329 - 3347, XP019652173
    - MARTIN-SUBERO, J. 1.; GESK, S.; HARDER, L.; SONOKI, T.; TUCKER, P. W.; SCHLEGELBERGER, B.; GROTE, W.; NOVO, F. J.; CALASANZ, M. J., "Recurrent involvement of the REL and BCL11A loci in classical Hodgkin lymphoma", BLOOD, (2002), vol. 99, pages 1474 - 1477
    - MATHAS, S.; HINZ, M.; ANAGNOSTOPOULOS, I.; KRAPPMANN, D.; LIETZ, A.; JUNDT, F.; BOMMERT, K.; MECHTA-GRIGORIOU, F.; STEIN, H.; D6RK, "Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B", EMBO J, (2002), vol. 21, pages 4104 - 4113
    - MATHAS, S.; JANZ, M.; HUMMEL, F.; HUMMEL, M.; WOLLERT-WULF, B.; LUSATIS, S.; ANAGNOSTOPOULOS, I.; LIETZ, A.; SIGVARDSSON, M.; JUND, "Intrinsic inhibition of transcription factor E2A by HLH proteins ABF-1 and Id2 mediates reprogramming of neoplastic B cells in Hodgkin lymphoma", NAT IMMUNOL, (2006), vol. 7, doi:doi:10.1038/ni1285, pages 207 - 215, XP009079152

DOI:   http://dx.doi.org/10.1038/ni1285
    - MOREAU, A.; PRALORAN, V.; BERRADA, L.; COUPEY, L.; GAILLARD, F., "Immunohistochemical detection of cells positive for colony-stimulating factor 1 in lymph nodes from reactive lymphadenitis, and Hodgkin's disease", LEUKEMIA, (1992), vol. 6, pages 126 - 130
    - NUTT, S. L.; KEE, B. L., "The transcriptional regulation of B cell lineage commitment", IMMUNITY, (2007), vol. 26, pages 715 - 725
    - OHSHIMA, K.; HARAOKA, S.; YOSHIOKA, S.; KAWASAKI, C.; TUTIYA, T.; SUZUMIYA, J.; KIKUCHI, M., "Chromosome 16q deletion and loss of E-cadherin expression in Hodgkin and Reed-Stemberg cells", INT J CANCER, (2001), vol. 92, pages 678 - 682
    - PIXLEY, F. J.; STANLEY, E. R., "CSF-1 regulation of the wandering macrophage: complexity in action", TRENDS CELL BIOL, (2004), vol. 14, doi:doi:10.1016/j.tcb.2004.09.016, pages 628 - 638, XP004618195

DOI:   http://dx.doi.org/10.1016/j.tcb.2004.09.016
    - PRINDULL, G.; ZIPORI, D., "Environmental guidance of normal and tumor cell plasticity: epithelial mesenchymal transitions as a paradigm", BLOOD, (2004), vol. 103, pages 2892 - 2899
    - ROUSSEL, M. F.; DULL, T. J.; RETTENMIER, C. W.; RALPH, P.; ULLRICH, A.; SHERR, C. J., "Transforming potential of the c-fms proto-oncogene (CSF-1 receptor)", NATURE, (1987), vol. 325, pages 549 - 552
    - SMIT, A. F., "Identification of a new, abundant superfamily of mammalian LTR-transposons", NUCLEIC ACIDS RES, (1993), vol. 21, pages 1863 - 1872
    - SOUABNI, A.; JOCHUM, W.; BUSSLINGER, M., "Oncogenic role of Pax5 in the T-lymphoid lineage upon ectopic expression from the immunoglobulin heavy-chain locus", BLOOD, (2007), vol. 109, pages 281 - 289
    - TAGOH, H.; INGRAM, R.; WILSON, N.; SALVAGIOTTO, G.; WARREN, A. J.; CLARKE, D.; BUSSLINGER, M.; BONIFER, C., "The mechanism of repression of the myeloid-specific c-fms gene by Pax5 during B lineage restriction", EMBO J, (2006), vol. 25, pages 1070 - 1080
    - USHMOROV, A.; LEITH5USER, F.; SAKK, O.; WEINHAUSEL, A.; POPOV, S. W.; MOLLER, P.; WIRTH, T., "Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma", BLOOD, (2006), vol. 107, doi:doi:10.1182/blood-2005-09-3765, pages 2493 - 2500, XP003021765

DOI:   http://dx.doi.org/10.1182/blood-2005-09-3765
    - VISVADER, J.; VERMA, I. M., "Differential transcription of exon 1 of the human c-fms gene in placental trophoblasts and monocytes", MOL CELL BIOL, (1989), vol. 9, pages 1336 - 1341
    - WALTER, K.; BONIFER, C.; TAGOH, H., "Stem cell-specific epigenetic priming and B cell-specific transcrintional activation at the mouse Cd19 locus", BLOOD, (2008), vol. 112, pages 1673 - 1682
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.